Ventricular Parasystole in Cardiomyopathy Patients
JACC: Clinical Electrophysiology · 2023
DOI: 10.1016/j.jacep.2022.11.014 ↗Kurz gefasst
Fachartikel in der Zeitschrift JACC: Clinical Electrophysiology, 2023. Verfasst von Duc H Do und 10 weiteren Autor:innen. Beteiligte Einrichtung: University of California, Los Angeles (UCLA) Cardiac Arrhythmia Center, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. Electr…. Hauptthemen laut MEDLINE: Parasystole, Tachycardia, Ventricular, Cardiomyopathies. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: NIH HHS, NHLBI.
Abstract (Originalsprache)
BACKGROUND: The clinical relevance and prognostic implications of ventricular parasystole are unknown. OBJECTIVES: This study sought to assess the prevalence of ventricular parasystole in patients with implantable cardioverter-defibrillators (ICDs) and ventricular parasystole's association with ventricular arrhythmias and conduction system abnormalities. METHODS: This study retrospectively evaluated patients who underwent ICD interrogation at a single center between June 1, 2019, and August 31, 2020, and reviewed all available ICD and electrocardiogram data. This study identified patients with ventricular parasystole and compared the prevalence of ventricular fibrillation (VF), ventricular tachycardia (VT), and new conduction system abnormalities in those with ≥5 years of intrinsic QRS-complex electrocardiograms to those without parasystole. RESULTS: This study included 374 patients (age 57 ± 21 years, 72% male, 45% nonischemic, 32% ischemic cardiomyopathy), of which, 104 (28%) had VT only, 39 (10%) VF only, and 10 (3%) both VT/VF. Ventricular parasystole was identified in 33 patients (9%); parasystolic foci were predominantly from the His-Purkinje system. Compared with those without parasystole, patients with parasystole had a significantly higher rate of VF (36% vs 11%; P < 0.01), but not VT (42% vs 29%; P = 0.12). Patients with parasystole, compared with those without parasystole, had a higher prevalence of new conduction abnormalities, particularly progressive intraventricular conduction delay (11 of 18 [61%] vs 12 of 83 [14%]; P < 0.01) and new right bundle branch block (4 of 18 [22%] vs 1 of 83 [1%]; P < 0.01). CONCLUSIONS: Ventricular parasystole was strongly associated with new conduction system abnormalities and VF in patients who have cardiomyopathy with ICDs, suggesting a potential link between VF and His-Purkinje damage in this patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of California, Los Angeles (UCLA) Cardiac Arrhythmia Center, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. Electronic address: ddo@mednet.ucla.edu.
- University of California, Los Angeles (UCLA) Cardiac Arrhythmia Center, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
- UCLA Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
- Cardiology, Academia Nacional de Medicina de Buenos Aires, Buenos Aires, Argentina.
Förderung
- NIH HHS
- NHLBI
Zitieren
APA
Do, D. H., O'Meara, K., Lee, J., Meyer, S., Hanna, P., Mori, S., Fishbein, M. C., Boyle, N. G., Elizari, M. V., Bradfield, J. S., & Shivkumar, K. (2023). Ventricular Parasystole in Cardiomyopathy Patients. JACC: Clinical Electrophysiology. https://doi.org/10.1016/j.jacep.2022.11.014
Vancouver
Do DH, O'Meara K, Lee J, Meyer S, Hanna P, Mori S, et al. Ventricular Parasystole in Cardiomyopathy Patients. JACC: Clinical Electrophysiology. 2023. doi:10.1016/j.jacep.2022.11.014
BibTeX
@article{Do2023,
author = {Do, Duc H and O'Meara, Kyle and Lee, Jiyoung and Meyer, Scott and Hanna, Peter and Mori, Shumpei and Fishbein, Michael C and Boyle, Noel G and Elizari, Marcelo V and Bradfield, Jason S and Shivkumar, Kalyanam},
title = {Ventricular Parasystole in Cardiomyopathy Patients},
journal = {JACC: Clinical Electrophysiology},
year = {2023},
doi = {10.1016/j.jacep.2022.11.014}
}
EUVIMED